HER2 Exon 20 Mutation
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy (NCT04447118) | Jiangsu HengRui Medicine Co., Ltd. | 2020-09-11 |
Track HER2 Exon 20 Mutation automatically
Every clearance here is in the API, with alerts when new ones post.